Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China

Background: Palbociclib has been approved for marketing in China. However, its effectiveness, safety, and latent variables in the Chinese population require further investigation. Methods: Information was retrieved from 397 patients with metastatic breast cancer (mBC) who received at least two cycles of palbociclib plus endocrine therapy (PAL plus ET) at eight clinical sites in China. The patients’ demographic characteristics, treatment patterns, and adverse events (AEs) were analyzed. Results: The objective response rate (ORR) and clinical benefit rate (CBR) for PAL plus ET were 28.97% and 66.25%, respectively. The median PFS was 14.2 months in the whole population. In addition to protein Ki-67 status and sensitivity to ETs, no liver metastases, fewer metastatic sites, an earlier line of therapy, and treatment combined with AI instead of FUL were also considered as independent prognostic factors for PAL treatment. Administration of PAL was generally well tolerated in patients with hormone-receptor-positive and human-epidermal-growth-factor-receptor-2-negative (HR+/HER2−) advanced breast cancer (ABC). The therapy was safe in the elderly population, which is consistent with the outcomes of the whole population and previous reports. Conclusions: In this most widely distributed study in China to date, palbociclib combined with ET proved its effectiveness for HR+/HER2− ABC treatment, and adverse events were manageable. Here, we identified some independent prognosis factors, but the mechanism by which these factors influence effectiveness requires further verification.

[1]  Frederick M. Howard,et al.  Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database , 2023, JAMA oncology.

[2]  S. Loi,et al.  Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 , 2022, Breast.

[3]  S. Loi,et al.  Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Lu Gan,et al.  Efficacy and safety of palbociclib plus endocrine therapy for patients with HR+/HER2− advanced breast cancer in real-world clinical practice , 2022, Annals of translational medicine.

[5]  R. Haidinger,et al.  Expert Discussion: Highlights from ABC6: Bridging the Gap and Insights in This First Virtual ABC Conference and from 10 Years ABC Consensus , 2021, Breast Care.

[6]  A. Schneeweiss,et al.  Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. , 2021, JAMA oncology.

[7]  S. Wang,et al.  228MO PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC) , 2021, Annals of Oncology.

[8]  B. Shao,et al.  The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis , 2021, Anti-cancer drugs.

[9]  A. Chinnaiyan,et al.  Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination , 2021, Nature Medicine.

[10]  Ting Li,et al.  Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[11]  A. Bardia,et al.  POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer. , 2020, Future oncology.

[12]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Gnant,et al.  Breast cancer , 2019, Nature Reviews Disease Primers.

[14]  H. Iwata,et al.  MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer , 2019, npj Breast Cancer.

[15]  K. Gelmon,et al.  Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up , 2019, Breast Cancer Research and Treatment.

[16]  S. Loi,et al.  Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer , 2018, The New England journal of medicine.

[17]  M. Ellis,et al.  CDK4/6 inhibition triggers anti-tumor immunity , 2017, Nature.

[18]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[19]  F. Penault-Llorca,et al.  Ki67 assessment in breast cancer: an update. , 2017, Pathology.

[20]  Ewout W Steyerberg,et al.  Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints , 2014, BMC Medical Research Methodology.

[21]  Wanqing Chen,et al.  Breast cancer in China. , 2014, The Lancet. Oncology.

[22]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.

[23]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[24]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.